To identify whether mental health wellbeing, age, gender or recent substance use pattern affected completion rates of a dual diagnosis inpatient program.
Method
This retrospective cohort study reviewed medical records of patients admitted between October 2018 and December 2021 of Westside Lodge, a dual diagnosis inpatient program. Demographic information, mental health screening tool results (BASIS-24) and self-reported substance use data were accessed from the patients’ electronic medical records.
Results
181 admissions were included in the study, of which the majority were male (53.6%). Recently used common substances were alcohol (52%), cannabis (40%) and methamphetamine (43%). None of the factors studied demonstrated any statistically significant effect on the likelihood of program completion.
Conclusion
This study found that age, gender, mental health wellbeing and recent substances used were not associated with the likelihood of completing inpatient dual diagnosis treatment though further high-powered studies are required to validate these claims.
LaiHHuangQ. Comorbidity of mental disorders and alcohol- and drug-use disorders: analysis of New South Wales inpatient data. Drug Alcohol Rev2009; 28: 235–242.
2.
RegierDFarmerMRaeD, et al.Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. JAMA1990; 264: 2511–2518.
3.
PriorKMillsKRossJ, et al.Substance use disorders comorbid with mood and anxiety disorders in the Australian general population. Drug Alcohol Rev2017; 36: 317–324.
4.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Comorbidity of substance use and mental disorders in Europe, EMCDDA insights. Luxembourg City, Luxembourg: Publications Office of the European Union, 2015.
5.
TeessonMSladeTMillsK. Comorbidity in Australia: findings of the 2007 national survey of mental health and wellbeing. Aust N Z J Psychiatr2009; 43: 606–614.
6.
HapangamaAKuruppuarachchiKPathmeswaranA. Substance use disorders among mentally ill patients in a general hospital in Sri Lanka: prevalence and correlates. Ceylon Med J2013; 58: 111–115.
7.
BorschmanRdos SantosMYoungJ, et al.Health, social and criminal justice factors associated with dual diagnosis among incarcerated adults in Brazil and Australia: a cross-national comparison. Soc Psychiatr Psychiatr Epidemiol2020; 55: 1355–1362.
8.
FridellMBackstromMHesseM, et al.Prediction of psychiatric comorbidity on premature death in a cohort of patients with substance use disorders: a 42-year follow-up. BMC Psychiatr2019; 19: 150–160.
9.
BaillargeonJPennJVKnightK, et al.Risk of reincarceration among prisoners with co-occurring severe mental illness and substance use disorders. Adm Policy Ment Health2010; 37: 367–374.
10.
Australian Institute of Health and Welfare. Alcohol and other drug treatment services in Australia 2017–18: key findings. Canberra, ACT: Australian Institute of Health and Welfare, 2019.
11.
BergmanBGreeneCSlaymakerV, et al.Young adults with co-occurring disorders: substance use disorder treatment response and outcomes. J Subst Abuse Treat2014; 46: 420–428.
12.
KrawczykNFederKSalonerB, et al.The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample. Drug Alcohol Depend2017; 175: 157–163.
13.
BrorsonHAjo ArnevikERand-HendriksenK, et al.Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev2013; 33: 1010–1024.
14.
SoferMKaptsanAAnsonJ. Factors associated with unplanned early discharges from a dual diagnosis inpatient detoxification unit in Israel. J Dual Diagn2018; 14: 137–147.
15.
DreyerJPooeJDzikitiL, et al.Factors associated with the successful completion of a substance rehabilitation programme at a psychiatric training hospital. S Afr J Psychiatr2020; 26: 1255.
16.
MaddenEFisherAMillsK, et al.Best practice approaches for alcohol and other drug treatment in residential settings. Evidence check prepared for the network of alcohol and other drug agencies (NADA). Darlington, NSW: The Matilda Centre for Research in Mental Health and Substance Use, 2021.
EisenSVNormandS-LBelangerAJ, et al.The revised behavior and symptom identification scale (BASIS-R): reliability and validity. Med Care2004; 42(12): 1230–1241. DOI: 10.1097/00005650-200412000-00010.
19.
EisenSRanganathanGSealP, et al.Measuring clinically meaningful change following mental health treatment. J Behav Health Serv Res2007; 34: 272–289.
20.
HarrisPATaylorRThielkeR, et al.Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf2009; 42(2): 377–381. DOI: 10.1016/j.jbi.2008.08.010.
DemirBSahinSElbogG, et al.Substance use characteristics, treatment completion rates and realted factors of patients at Gaziantep AMATEM in 2019; a retrosepctive study. J Subst Use2022; 27: 128–134.
23.
DarkeSCampbellGPoppleG. Retention, early dropout and treatment completion among therapeutic community admissions. Drug Alcohol Rev2012; 31: 64–71.
24.
Australian Institute of Health and Welfare. National drug strategy household survey 2019. Canberra, ACT: AIHW, Australian Government, 2020.
25.
RedkoCRappRCCarlsonRG. Waiting time as a barrier to treatment entry: perceptions of substance users. J Drug Issues2006; 36(4): 831–852. DOI: 10.1177/002204260603600404.
